-
FGFR1 as a Druggable Target in Schizophrenia
2026-08-21
A 2025 Molecular Neurobiology study integrated eQTL, GWAS, Mendelian randomization, co-localization, SMR, phenome-wide association, docking, and single-cell analyses to prioritize six druggable genes for schizophrenia. FGFR1 emerged as the leading candidate, although the results represent target prioritization rather than evidence of clinical efficacy.
-
PEP Restricts cGAS Inflammation During Aging
2026-08-20
The reference study identifies phosphoenolpyruvate (PEP) as an endogenous, age-regulated inhibitor of cGAS-driven inflammation. By combining longitudinal profiling, plasma-transfer experiments, metabolic perturbation, binding analyses, and an Alzheimer’s disease model, it connects glycolytic metabolism with inflammaging and healthy aging.
-
Psora 4 Workflows for Kv1.3 T Cell Research
2026-08-20
Psora 4 is a selective Kv1.3 blocker for connecting ion-channel pharmacology with T-cell proliferation, calcium flux, and inflammatory readouts. This workflow-focused guide shows how to prepare the compound, design orthogonal assays, account for KCNE4-dependent kinetics, and interpret immune-model data without overstating translational conclusions.
-
Pomalidomide (CC-4047) for Myeloma Assays
2026-08-19
Pomalidomide (CC-4047) supports genotype-aware multiple myeloma assays that connect cytokine modulation, tumor-cell response, and erythroid biology. This workflow-focused guide shows how to formulate the compound, select meaningful concentration ranges, integrate mutational data, and troubleshoot reproducibility problems.
-
Risedronate Sodium: Translational Workflows
2026-08-19
Risedronate Sodium combines a defined FPPS-inhibition mechanism with practical opportunities in osteoclast assays, nano-delivery, transdermal patches, and exploratory pulmonary models. This guide translates published formulation performance into executable workflows, assay controls, and troubleshooting decisions.
-
5-Azacytidine: From DNMT Biology to Leukemia Strategy
2026-08-18
5-Azacytidine is more than a conventional DNA methylation tool: its DNMT-trapping chemistry provides a framework for connecting epigenetic reprogramming with leukemia-cell vulnerability. This thought-leadership guide interprets new evidence on the dual DNMT–tubulin inhibitor H62 and translates it into practical, strategically designed workflows for leukemia, multiple myeloma, and broader cancer research.
-
Z-VAD-FMK for Reliable Apoptosis Assays
2026-08-18
This scenario-driven guide explains how Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone), SKU A1902, can help researchers distinguish caspase-dependent apoptosis from alternative cell-death mechanisms. It covers assay design, DMSO handling, interpretation, and practical vendor-selection criteria.
-
Betulinic Acid and ERK in Cyclophosphamide Liver Injury
2026-08-17
This study identifies an ERK-linked mitochondrial apoptosis mechanism underlying cyclophosphamide-induced liver injury and shows that betulinic acid reduces oxidative damage through NRF2 activation and MAPK suppression. Pharmacological pathway interrogation with PD98059 strengthens the conclusion that ERK signaling connects redox imbalance, mitochondrial dynamics, and hepatocyte apoptosis.
-
c-Myc Tag Peptide: From Assay Control to Translation
2026-08-17
The c-Myc tag Peptide is more than a blocking reagent: it is a precision control for testing epitope-dependent immunoassay signals and strengthening translational conclusions about transcription-factor biology. This article connects c-Myc assay mechanics with evidence on IRF3 stability, selective autophagy, and immune regulation while defining practical validation strategies and important limits.
-
TRPV1/TRPA1 Control of TSLP in Nasal Epithelium
2026-08-16
The reference study identifies a calcium-dependent NFAT mechanism linking TRPV1 and TRPA1 activation in nasal epithelial cells to TSLP production. Its combined use of pharmacological perturbation, siRNA, calcium chelation, and NFAT localization provides a useful framework for interpreting epithelial ion-channel signaling in upper-airway inflammation.
-
Omeprazole (A2845): Practical Research Guide
2026-08-15
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for gastric acid secretion research, assay benchmarking, and selected antiulcer activity studies. This guide focuses on dossier-supported handling and workflow controls; the compound is for scientific research only and should not be used for diagnosis, treatment, or medical decision-making.
-
Foxp1, Notch, and Valvular Calcification in CKD
2026-08-14
The 2026 Biochemical Pharmacology study identifies endothelial Foxp1 as a suppressor of CKD-associated valvular calcification by restraining Jagged-1/Notch activation and endothelial-to-mesenchymal transition. Its findings connect endothelial barrier preservation with reduced TGF-β1-driven osteogenic remodeling and HMGB1-associated inflammation, offering a mechanistic framework for studying PTH-linked valve disease.
-
PTH (1-34) and CKD Valvular Calcification
2026-08-14
Parathyroid hormone (1-34) (human) is more than a bone biology reagent: it is a controllable probe for connecting receptor-proximal calcium signaling with endothelial-to-mesenchymal transition and chronic kidney disease-associated valvular calcification. This article interprets recent Foxp1–Notch findings, positions the PTH (1-34) peptide fragment within translational workflows, and outlines experimental strategies that separate acute receptor activation from chronic endocrine pathology.
-
QPRT, P2Y11 Signaling, and Breast Cancer Invasion
2026-08-13
Liu et al. connect elevated quinolinate phosphoribosyltransferase (QPRT) with breast cancer migration and invasion through a purinergic signaling axis associated with myosin light-chain phosphorylation. Their combined genetic and pharmacological experiments provide a mechanistic framework for studying how NAD+ metabolism may influence tumor-cell mechanics and identify experimental considerations for P2Y11 pathway studies.
-
FAK Inhibitor 14 for Reliable Cell Assays
2026-08-13
This scenario-driven guide explains how FAK Inhibitor 14, SKU B7400, can help researchers distinguish FAK-dependent signaling from nonspecific assay artifacts in viability, proliferation, migration, and EMT experiments. It combines product specifications with findings from cholesterol-resistant ovarian cancer research to support practical, reproducible study design.